Comprehensive asthma management: Guidelines for clinicians

Journal of Asthma

Volumn 35, Issue 8, 1998, Pages 601-620

  Kemp, James P ^a,b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b Asthma and Allergy Research Group and Medical Center   (United States)

Author keywords

Airway inflammation; Antiasthma drugs; Corticosteroids; Leukotrienes

Indexed keywords

ANTIASTHMATIC AGENT; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIPOXYGENASE INHIBITOR; MONTELUKAST; ZAFIRLUKAST; ZILEUTON;

ASTHMA; HEALTH CARE COST; HUMAN; LUNG FUNCTION; MORBIDITY; PRACTICE GUIDELINE; REVIEW; SYMPTOM;

EID: 0032443434     PISSN: 02770903     EISSN: None     Source Type: Journal    
DOI: 10.3109/02770909809048963     Document Type: Review

References (90)

1. National Heart, Lung, and Blood Institute: Asthma Management and Prevention. A Practical Guide for Public Health Officials and Health Care Professionals. Publication No. 96-3659A. National Institutes of Health, Bethesda, MD, 1995.
2. National Asthma Education and Prevention Program. Guidelines for the Diagnosis and Management of Asthma. Expert Panel Report 2. National Institutes of Health, Bethesda, MD, 1997.
3. National Asthma Education Program. Guidelines for the Diagnosis and Management of Asthma. Publication No. 91-3042. National Institutes of Health, Bethesda, MD, 1991.
4. Sly RM: Changing asthma mortality and sales of inhaled bronchodilators and antiasthmatic drugs. Ann Allergy 73:439-443 (1994).
5. Sly RM: Changing asthma mortality. Ann Allergy 73: 259-268 (1994).
6. Beasley R, Burgess C, Crane J, et al: Pathology of asthma and its clinical implications. J Allergy Clin Immunol 92:148-154 (1993).
7. Howarth PH, Bradding P, Quint D, et al: Cytokines and airway inflammation. Ann N Y Acad Sci 725:69-82 (1994).
8. Cockroft DW: Airway hyperresponsiveness: therapeutic implications. Ann Allergy 59:405-414 (1987).
9. Gleich GJ, Flavahan NA, Fujisawa T, et al: The eosinophil as a mediator of damage to respiratory epithelium: a model for bronchial hyperreactivity. J Allergy Clin Immunol 81:776-781 (1988).
10. Hogg JC: Pathology of asthma. J Allergy Clin Immunol 92:1-5 (1993).
11. Larsen GL: The late asthmatic response. Chest 93: 1287-1289 (1988).
12. O'Byrne PM, Dolovich J, Hargreave FE: Late asthmatic responses. Am Rev Respir Dis 136:740-751 (1987).
13. De Monchy JG, Kauffman HF, Venge P, et al: Bronchoalveolar eosinophilia during allergen-induced late asthmatic reactions. Am Rev Respir Dis 131:373-376 (1985).
14. Kemp JP: Approaches to asthma management. Realities and recommendations. Arch Intern Med 153:805-812 (1993).
15. Beasley R, Roche WR, Roberts JA, et al: Cellular events in the bronchi in mild asthma and after bronchial provocation. Am Rev Respir Dis 139:806-817 (1989).
16. Israel E, Cohn J, Dube L, et al: Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. JAMA 275:931-936 (1996).
17. Adachi JD: Corticosteroid-induced osteoporosis. Am J Med Sci 313:41-49 (1997).
18. Adachi JD, Bensen WG, Bianchi F, et al: Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year follow-up. J Rheumatol 23:995-1000 (1996).
19. Djukanovic R, Wilson JW, Britten KM, et al: Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am Rev Respir Dis 145:669-674 (1992).
20. Hanania NA, Chapman KR, Kesten S: Adverse effects of inhaled corticosteroids. Am J Med 98:196-208 (1995).
21. Potential adverse endocrine effects of inhaled corticosteroids. J Paed Child Health 32:278-280 (1996).
22. Toogood JH, Baskerville JC, Markov AE, et al: Bone mineral density and the risk of fracture in patients receiving long-term inhaled steroid therapy for asthma. J Allergy Clin Immunol 96:157-166 (1995).
23. Hoag JE, McFadden ER Jr: Long-term effect of cromolyn sodium on nonspecific bronchial responsiveness: a review. Ann Allergy 66:53-63 (1991).
24. 2-adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients. Thorax 43: 674-678 (1988).
25. Johnson M: Salmeterol: a novel drug for the treatment of asthma. Agents Actions Suppl 34:79-95 (1991).
26. Kemp JP, Dockhorn RJ, Busse WW, et al: Prolonged effect of inhaled salmeterol against exercise-induced bronchospasm. Am J Respir Crit Care Med 150:1612-1615 (1994).
27. Greening AP, Ind PW, Northfield M, et al: Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 344:219-224 (1994).
28. 2-agonist formoterol. Am Rev Respir Dis 143:998-1001 (1989).
29. Rabe KF, Jorres R, Nowak D, et al: Comparison of the effects of salmeterol and formoterol on airway tone and responsiveness over 24 hours in bronchial asthma. Am Rev Respir Dis 147:1436-1441 (1993).
30. 2-adrenergic receptor agonist: double-blind comparison with salbutamol and placebo in children with asthma. J Allergy Clin Immunol 84:891-895 (1989).
31. Yates DH, Sussman HS, Shaw MJ, et al: Regular formoterol treatment in mild asthma. Effect on bronchial responsiveness during and after treatment. Am J Respir Crit Care Med 152:1170-1174 (1995).
32. Finnerty JP, Lee C, Wilson S, et al: Effects of theophylline on inflammatory cells and cytokines in asthmatic subjects: a placebo-controlled parallel group study. Eur Respir J 9:1672-1677 (1996).
33. Djukanovic R, Finnerty JP, Lee C, et al: The effects of theophylline on mucosal inflammation in asthmatic airways: biopsy results. Eur Respir J 8:831-833 (1995).
34. Banner KH, Page CP: Theophylline and selective phosphodiesterase inhibitors as anti-inflammatory drugs in the treatment of bronchial asthma. Eur Respir J 8:996-1000 (1995).
35. Sullivan P, Bekir S, Jaffar Z, et al: Anti-inflammatory effects of low-dose oral theophylline in atopic asthma. Lancet 343:1006-1008 (1994).
36. Torphy TJ, Undem BJ: Phosphodiesterase inhibitors: new opportunities for the treatment of asthma. Thorax 46:512-523 (1991).
37. McFadden ER Jr, Gilbert IA: Exercise-induced asthma. N Engl J Med 1994; 330:1362-1367.
38. Bone RC. Goals of asthma management. A step-care approach. Chest 109:1056-1065 (1996).
39. Nimmagadda SR, Spahn, JD, Leung DY, Szefler SJ: Steroid-resistant asthma: evaluation and management. Ann Allergy Asthma Immunol 77:345-355 (1996).
40. Sher ER, Leung DY, Surs W, et al: Steroid-resistant asthma. Cellular mechanisms contributing to inadequate response to glucocorticoid therapy. J Clin Invest 93:33-39 (1994).
41. Bryant DH, Rogers P: Effects of ipratropium bromide nebulizer solution with and without preservatives in the treatment of acute and stable asthma. Chest 102: 742-747 (1992).
42. Rebuck AS, Chapman KR, Abboud R, et al: Nebulized anticholinergic and sympathomimetic treatment of asthma and chronic obstructive airways disease in the emergency room. Am J Med 82:59-64 (1987).
43. Morrison JF, Pearson SB, Dean HG: Parasympathetic nervous system in nocturnal asthma. Br Med J 296: 1427-1429 (1988).
44. Gross NJ. Ipratropium bromide. N Engl J Med 319: 486-494 (1988).
45. Evans RE III: Environmental control and immunotherapy for allergic disease. J Allergy Clin Immunol 90: 462-468 (1992).
46. Kotses H, Lewis P, Creer TL: Environmental control of asthma self-management. J Asthma 27:375-384 (1990).
47. Boulet LP, Giguere MC, Milot J, et al: Effects of long-term use of high-dose inhaled steroids on bone density and calcium metabolism. J Allergy Clin Immunol 94:796-803 (1994).
48. Meeran K, Hattersley A, Burrin J, et al: Oral and inhaled corticosteroids reduce bone formation as shown by plasma osteocalcin levels. Am J Respir Crit Care Med 151:333-336 (1995).
49. Chervinsky P, van As A, Bronsky EA, et al: Fluticasone propionate aerosol for the treatment of adults with mild to moderate asthma. J Allergy Clin Immunol 94:676-683 (1994).
50. Noonan M, Chervinsky P, Busse WW, et al: Fluticasone propionate reduces oral prednisone use while it improves asthma control and quality of life. Am J Respir Crit Care Med 152:1467-1473 (1995).
51. Booth H, Richmond I, Ward C, et al: Effect of high dose inhaled fluticasone propionate on airway inflammation in asthma. Am J Respir Crit Care Med 152: 45-52 (1995).
52. Bootsma GP, Dekhuijzen PNR, Festen J, et al: Fluticasone propionate does not influence bone metabolism in contrast to beclomethasone dipropionate. Am J Respir Crit Care Med 153:924-930 (1996).
53. Gauvreau GM, Doctor J, Watson RM, et al: Effects of inhaled budesonide on allergen-induced airways responses and airway inflammation. Am J Respir Crit Care Med 154:1267-1271 (1996).
54. Clark DJ, Clark RA, Lipworth BJ: Adrenal suppression with inhaled budesonide and fluticasone propionate given by large volume spacer to asthmatic children. Thorax 51:941-943 (1996).
55. Clark DJ, Grove A, Cargill RI, Lipworth BJ: Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients. Thorax 51:262-266 (1996).
56. Samuelsson B, Dahlen SE, Lindgren JA, et al: Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 237:1171-1176 (1987).
57. Abramovitz M, Wong E, Cox ME, et al: 5-Lipoxygenase-activating protein stimulates the utilization of arachidonic acid by 5-lipoxygenase. Eur J Biochem 215: 105-111 (1993).
58. 4, and histamine in normal human subjects. Thorax 39:500-504 (1984).
59. 4 and granulocytic infiltration into asthmatic airways. Lancet 341:989-990 (1993).
60. Palmer RM, Stepney RJ, Higgs GA, et al: Chemokinetic activities of arachidonic and lipoxygenase products on leukocytes of different species. Prostaglandins 20:411-418 (1980).
61. 4 action on endothelium mediates augmented neutrophil/endothelial adhesion. Proc Natl Acad Sci USA 81:2191-2193 (1984).
62. 4 in the human lung. Recruitment of neutrophils into the alveolar spaces without a change in protein permeability. J Clin Invest 84:1609-1619 (1989).
63. 4-induced bronchoconstriction in subjects with asthma. A concentration-effect study of ICI-204,219. Clin Pharmacol Ther 54:430-436 (1993).
64. 4 receptor antagonism in the airways of asthmatics. Am J Respir Crit Care Med 149:A465 (1994).
65. 4 receptor antagonist. Am Rev Respir Dis 145:746-749 (1992).
66. 4 antagonist, inhibits exercise induced bronchoconstriction in asthmatics at the end of a once daily dosing schedule. Am J Respir Crit Care Med 151:A377 (1995).
67. Findlay SR, Barden JM, Easley CB, Glass M: Effect of the oral leukotriene antagonist, ICI 204,219, on antigen-induced bronchoconstriction in subjects with asthma. J Allergy Clin Immunol 89:1040-1045 (1992).
68. Taniguchi Y, Tamura G, Honma M, et al: The effect of an oral leukotriene antagonist, ONO-1078, on allergen-induced immediate bronchoconstriction in asthmatic subjects. J Allergy Clin Immunol 92:507-512 (1993).
69. 4) receptor antagonist, in patients with chronic asthma. J Allergy Clin Immunol 98:528-534 (1996).
70. 1-receptor antagonist, improves signs and symptoms of asthma with a dose as low as 10 mg once daily, in press.
71. 4 receptor antagonist, in subjects with bronchial asthma. Am J Respir Crit Care Med 150:618-623 (1994).
72. 4) receptor antagonist (MK-571) in patients with asthma. Am Rev Respir Dis 146:358-363 (1992).
73. Dahlén B, Margolskee DJ, Zetterstrom O, et al: Effect of the leukotriene receptor antagonist MK-0679 on baseline pulmonary function in aspirin sensitive asthmatic subjects. Thorax 48:1205-1210 (1993).
74. Diamant Z, Timmers MC, van der Veen H, et al: The effect of MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allergen-induced airway responses in asthmatic subjects in vivo. J Allergy Clin Immunol 95:42-51 (1995).
75. Friedman BS, Bel EH, Buntinx A, et al: Oral leukotriene inhibitor (MK-886) blocks allergen-induced airway responses. Am Rev Respir Dis 147:839-844 (1993).
76. Storms W, Friedman BS, Zhang J, et al: Treating asthma by blocking the lipoxygenase pathway. Am J Respir Cell Mol Biol 151:A377 (1995).
77. H2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 326:298-304 (1992).
78. Van Oosterhout AJ, Ladenius AR, Sayelkoul HF, et al: Effect of anti-IL-5 and IL-5 on airway hyperreactivity and eosinophils in guinea pigs. Am Rev Respir Dis 147:548-552 (1993).
79. Milne AA, Piper PJ: Effects of interleukin-5 inhibition on antigen-induced airway hyperresponsiveness and cell accumulation in guinea pigs. Ann N Y Acad Sci 725:282-287 (1994).
80. Weller PF, Rand TH, Goelz SE, et al: Human eosinophil adherence to vascular endothelium mediated by binding to vascular cell adhesion molecule 1 and endothelial leukocyte adhesion molecule 1. Proc Natl Acad Sci USA 88:7430-7433 (1991).
81. 4-Integrins mediate antigen-induced late bronchial responses and prolonged airway hyperresponsiveness in sheep. J Clin Invest 93:776-787 (1994).
82. Barnes PJ, Chung KF, Page CP: Platelet-activating factor as a mediator of allergic disease. J Allergy Clin Immunol 81:919-934 (1988).
83. Barnes NC: New developments in the treatment of asthma and chronic obstructive pulmonary disease. Respir Med 87(Suppl B):53-56 (1993).
84. Cheung D, Timmers MC, Zwinderman AH, et al: Neutral endopeptidase activity and airway hyperresponsiveness to neurokinin A in asthmatic subjects in vivo. Am Rev Respir Dis 148:1467-1473 (1993).
85. Ichinose M, Nakajima N, Takahashi T, et al: Protection against bradykinin-induced bronchoconstriction in asthmatic patients by neurokinin receptor antagonist. Lancet 340:1248-1251 (1992).
86. Kelly SJ, Uri AJ, Freeland HS, et al: Effects of colchicine on IgE-mediated early and late airway reactions. Chest 107:985-991 (1995).
87. Virchow JC Jr, Kroegel C, Matthys H: Antiasthma drug delivery. What is on the horizon? Clin Pharmacokinet 27:85-93 (1994).
88. DeBlaquiere P, Christensen DB, Carter WB, Martin TR: Use and misuse of metered-dose inhalers by patients with chronic lung disease. Am Rev Respir Dis 140:910-916 (1989).
89. Rand CS, Wise RA: Measuring adherence to asthma medication regimens. Am J Respir Crit Care Med 149: S69-S76 (1994).
90. Newnham DM, Lipworth BJ: Nebulizer performance, pharmacokinetics, airways and systemic effects of salbutamol given via a novel nebulizer delivery system ("Ventstream"). Thorax 49:762-770 (1994).